


















































































the	high–carbohydrate,	 high–fat	 diet.	Within	 the	 first	week	of	 the	diet	 switch,	 plasma	
triglycerides	were	halved	and	there	was	a	significant	decrease	in	omental	fat,	kidney	and	
liver	tissue	weights.	Diastolic	stiffness,	heart	inflammation	and	liver	fat	deposition	were	
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5%	 in	1975	 to	13%	 in	2014,	 and	 is	 expected	 to	 reach	20%	by	2025	 if	 current	 trends	















if	 the	 body	 mass	 index	 (BMI)	 of	 at	 risk	 individuals	 was	 decreased	 by	 1	 kg/m2	









































to	 the	 restriction	 of	 blood	 flow	 to	 the	 heart	 and	 brain,	 respectively	 (Lu	 et	 al.	 2014b).	
Elevated	 fasting	 blood	 glucose	 is	 indicative	 of	 insulin	 resistance,	 which	 results	 from	




When	 energy	 intake	 exceeds	 energy	 expenditure,	 surplus	 nutrients	 are	 stored	 for	 use	
during	 times	of	 scarce	 food	 availability.	Unused	 glucose	 is	 stored	within	 the	 liver	 and	
skeletal	muscles	as	the	branched	polysaccharide	glycogen.	Once	the	glycogen	stores	are	
replenished,	the	remaining	glucose	is	converted	to	lipids	within	the	liver	via	the	process	
of	 de	 novo	 lipogenesis	 (Lu	 et	 al.	 2014a).	 Dietary	 and	 synthesised	 free	 fatty	 acids	 are	
transported	 through	 the	 bloodstream	 within	 lipoproteins,	 which	 vary	 in	 density	
depending	 on	 the	 ratio	 of	 lipids	within	 the	 hydrophobic	 core	 and	 proteins	within	 the	





Circulating	 lipoproteins	are	degraded	by	endothelial	 lipoprotein	 lipases,	 releasing	 free	
fatty	 acids	 that	 surrounding	 cells	 break	 down	 and	 use	 for	 energy	 production	 (Griffin	
2013).	 Excess	 free	 fatty	 acids	 are	 converted	 to	 triglycerides	 and	 stored	 within	 white	
adipocytes,	the	only	cell	type	that	is	adapted	to	store	lipids	without	impairing	function	
(Hajer,	 van	Haeften	&	 Visseren	 2008).	 Chronic	 consumption	 of	 a	 diet	 rich	 in	 fats	 and	
simple	carbohydrates	increases	lipid	deposition	within	white	adipocytes	and	promotes	
adipose	 tissue	 expansion	 (Hoffstedt	 et	 al.	 2010).	 Metabolically	 healthy	 adipose	 tissue	




for	 cell	 function,	 as	 excessive	 lipid	 accumulation	 induces	 toxic	 effects	 (Hoffstedt	 et	 al.	
2010;	Muir	et	al.	2018).	
	
Adipose	 tissue	expansion	 is	accompanied	by	angiogenesis,	 the	 formation	of	new	blood	




irreparable	 damage	 due	 to	 hypoxia	 undergo	 necrotic	 cell	 death,	which	 stimulates	 the	
infiltration	 of	 macrophages	 that	 surround	 dying	 adipocytes	 and	 form	 “crown–like”	
histological	 structures	 (Murano	 et	 al.	 2008).	 The	 macrophages	 within	 obese	 adipose	
tissue	 tend	 to	have	an	 inflammation–promoting	M1	phenotype,	whereas	metabolically	





White	 adipose	 tissue	 is	 not	merely	 a	 storage	 site	 for	 excess	 fatty	 acids,	 but	 is	 also	 an	
essential	endocrine	organ	involved	in	regulating	satiety,	metabolism	and	inflammation.	
These	effects	are	mediated	by	adipokines,	the	bioactive	proteins	produced	by	adipocytes	



















a	 state	 of	 chronic	 low–grade	 inflammation.	 Increased	 secretion	 of	 pro–inflammatory	
adipokines,	 including	 leptin,	 tumour	 necrosis	 factor–alpha	 (TNF–α)	 and	 interleukin–6	
(IL–6),	during	obesity	contributes	to	the	development	of	metabolic	dysfunction,	insulin	
resistance	and	cardiovascular	disease	(Ouchi	et	al.	2011).	This	systemic	inflammation	is	




















Cardiac	 remodelling	 is	 most	 prominent	 among	 severely	 obese	 individuals	 and	 in	 the	























obstructive	 sleep	 apnoea	 (OSA),	 that	 place	 additional	 burden	 on	 the	 heart.	 Left	 ventricular






 Obesity–related	 co–morbidities	 currently	 cost	 the	 Australian	 economy	 $8.6	 billion	
dollars	
 Drug	 interventions	 can	 be	 used	 in	 conjunction	 with	 diet	 changes	 and	 exercise,	
although	often	have	unpleasant	side	effects.	E.g.	orlistat,	a	gastric	lipase	inhibitor,	is	
associated	 with	 abdominal	 pain,	 faecal	 urgency	 and	 loose,	 oily	 stools.	 Three	 anti‐
obesity	drugs	have	also	been	withdrawn	from	the	market	in	the	past	decade	due	to	
serious	adverse	events:	rimonabant	failed	FDA	approval	in	the	US	and	was	withdrawn	
from	 European	 market	 in	 2009	 due	 to	 concerning	 psychiatric	 effects,	 benfluorex	






improving	 overall	 health,	 although	 have	 limited	 long‐term	 efficacy	 due	 to	 poor	
compliance.	Weight	regain	is	also	common,	which	is	potentially	due	to	a	prolonged	
decrease	in	metabolic	rate	after	weight	loss		(Fothergill	et	al.	2016).	
 Thus,	 there	 is	 an	 urgent	 need	 for	 safer	 and	 more	 effective	 obesity	 treatments.	






























All	 experimental	 protocols	were	 approved	 by	 the	 University	 of	 Southern	 Queensland	
Animal	 Ethics	 Committee	 (Project	 number	 –	 17REA003)	 under	 the	 guidelines	 of	 the	
National	 Health	 and	Medical	 Research	 Council	 of	 Australia.	 For	 this	 project,	 84	male	
Wistar	rats	(8–9	weeks	old,	335	±	5	g)	were	purchased	from	the	Animal	Resource	Centre,	
Murdoch,	WA,	Australia.	After	arrival,	rats	were	fed	a	standard	laboratory	chow	diet	and	











The	 experimental	 protocol	 is	 outlined	 in	 Figure	 2–1.	 All	 rats	were	 housed	within	 the	











powdered	 rat	 food	was	 purchased	 from	 Specialty	 Feeds,	 Glen	 Forrest,	WA,	 Australia.	
Hubble,	Mendel	and	Wakeman	salt	mixture	was	purchased	from	MP	Biomedicals,	Seven	
Hills,	NSW,	Australia.	Fructose	was	purchased	from	Tate	&	Lyle,	Wacol,	QLD,	Australia.	
Corn	 starch	 was	 purchased	 from	 Agri	 Food	 Ingredients,	 Kew	 East,	 VIC,	 Australia.	 All	




































and	 Wakeman	 salt	 mixture	 and	 250mL	 water	 per	 kilogram	 of	 food.	 The	 HCHF	 diet	





































mass,	 bone	 mineral	 content	 and	 bone	 mineral	 density	 were	 analysed	 using	 the	











strip	 (Abbott	 Diabetes	 Care	 Inc.,	 Doncaster,	 VIC,	 Australia)	 attached	 to	 a	 FreeStyle	
Freedom	Lite	 glucometer	 (Abbott	Diabetes	 Care	 Inc.).	 Rats	were	 administered	 a	 40%	
aqueous	glucose	solution	(2g	glucose/kg	body	weight)	via	oral	gavage.	Tail	vein	blood	
samples	were	taken	at	30,	60,	90	and	120	minutes	after	glucose	administration	(Panchal	










and	water	 intakes	were	 recorded	and	 rats	were	 returned	 to	 their	normal	 cages.	Heat	





Systolic	 blood	 pressure	was	measured	 at	 the	 beginning	 and	 end	 of	 protocol,	 with	 an	
additional	measurement	performed	for	C,	H	and	H8C8	rats	at	week	8,	using	a	MLT844	
Physiological	Pressure	Transducer	(ADInstruments,	Sydney,	NSW,	Australia)	connected	
to	 a	 PowerLab	 data	 acquisition	 unit	 (ADInstruments).	 Rats	were	 anaesthetised	 using	














modified	 Krebs–Henseleit	 bicarbonate	 buffer,	 which	 consisted	 of	 (in	 mmol/L):	 119.1	
NaCl,	4.75	KCl,	1.19	MgSO4,	1.19	KH2PO4,	25.0	NaHCO3,	11.0	glucose	and	2.16	CaCl2.	The	
buffer	was	bubbled	with	95%	O2–5%	CO2	and	maintained	at	35°C.	A	latex	balloon	catheter	


















buffered	 formalin.	 After	 three	 days,	 the	 samples	 were	 processed	 and	 embedded	 in	
paraffin	wax.	Thin	sections,	5	µm	in	size,	were	cut	and	stained	with	haematoxylin	and	
eosin	 for	 determination	 of	 inflammatory	 cell	 infiltration	 (20×)	 and	 liver	 fat	 vacuole	
presence	(20×)	(Panchal	et	al.	2011).	Two	slides	were	prepared	per	tissue	specimen	and	





the	 concentrations	 of	 lipids	 and	 liver	 damage	 biomarkers.	 Plasma	 total	 cholesterol,	





















































H	 and	 H8C8	 rats	 and	 was	 similar	 to	 the	 C	 group.	 Food	 conversion	 efficiency	 was	
































Variable	 C	 H	 H8C8	 P–value	
Initial	body	weight	(g)	 338	±	1	 341	±	1	 338	±	1	 0.0620	
Body	weight	at	8	weeks	(g)	 373	±	5	a	 444	±	6	b	 431	±	8	b	 <	0.0001	
Final	body	weight	(g)	 408	±	6	a	 512	±	6	b	 444	±	9	c	 <	0.0001	
Water	intake	0‐8	weeks	
(mL/day)	 33.7	±	2.4	a	 25.8	±	1.6	b	 25.1	±	2.2	b	 0.0105	
Water	intake	8‐16	weeks	
(mL/day)	 32.1	±	2.3	 30.4	±	1.0	 30.6	±	2.4	 0.8003	
Food	intake	0‐8	weeks	
(g/day)	 42.7	±	1.0	a	 29.6	±	1.4	b	 26.6	±	1.0	b	 <	0.0001	
Food	intake	8‐16	weeks	
(g/day)	 41.7	±	1.1	a	 28.1	±	0.8	b	 40.8	±	1.0	a	 <	0.0001	
Energy	intake	0‐8	weeks	
(kJ/day)	 479	±	11	b	 626	±	31	a	 568	±	27	a	 0.0006	
Energy	intake	8‐16	weeks	
(kJ/day)	 469	±	13	b	 618	±	16	a	 460	±	9	b	 <	0.0001	
Food	conversion	efficiency		
0‐8	weeks	(g/kJ)	 0.073	±	0.011	b	 0.166	±	0.006	a	 0.164	±	0.012	a	 <	0.0001	
Food	conversion	efficiency		
8‐16	weeks	(g/kJ)	 0.077	±	0.006	







Variable	 H8	 H8C1	 H8C2	 H8C4	 H8C8	 P–value	
Initial	body	weight	(g)	 340	±	1	 339	±	1	 341	±	1	 339	±	1	 338	±	1	 0.3063	
Body	weight	8	weeks	(g)	 439	±	6	 457	±	11	 461	±	9	 459	±	10	 431	±	8	 0.0824	
Final	body	weight	(g)	 439	±	6	 443	±	10	 441	±	7	 442	±	10	 444	±	9	 0.9953	
Water	intake	0‐8	weeks	(mL/day)	 33.3	±	0.9	a	 32.2	±	1.1	a	 31.5	±	1.1	a	 32.2	±	1.4	a	 25.1	±	2.2	b	 0.0011	
Water	intake	after	diet	switch	
(mL/day)	 N/A	 34.5	±	1.8	 33.3	±	1.1	 35.0	±	1.3	 30.6	±	2.4	 0.2949	
Food	intake	0‐8	weeks	(g/day)	 28.7	±	0.9	ab	 28.2	±	1.0	ab	 31.4	±	1.2	a	 30.1	±	1.4	ab	 26.6	±	1.0	b	 0.0369	
Food	intake	after	diet	switch	(g/day)	 N/A	 33.5	±	1.2	a*	 40.0	±	1.3	b*	 44.0	±	1.1	b*	 40.8	±	1.0	b*	 <	0.0001	
Energy	intake	0‐8	weeks	(kJ/day)	 646	±	15	ab	 633	±	19	ab	 683	±	24	a	 575	±	26	b	 568	±	27	b	 0.0030	
Energy	intake	after	diet	switch	(kJ/day)	 N/A	 376	±	13	c*	 450	±	15	b*	 495	±	12	a*	 460	±	9	ab*	 <	0.0001	
Food	conversion	efficiency	0‐8	weeks	
(g/kJ)	 0.153	±	0.010	b	 0.185	±	0.014	ab	 0.184	±	0.009	ab	 0.213	±	0.019	a	 0.164	±	0.012	b	 0.0122	
Food	conversion	efficiency	after	diet	
















the	 H	 and	 H8C8	 rats	 (P	 <	 0.0001).	 The	 C	 rats	 had	 a	 significantly	 lower	 abdominal	
circumference	compared	 to	 the	H	and	H8C8	rats	at	both	8	and	16	weeks	 (P	<	0.001).	
Despite	 having	 a	 similar	 abdominal	 circumference	 at	 8	 weeks,	 the	 H	 group	 had	 a	















Variable	 C	 H	 H8C8	 P–value	
Bone	mineral	content	at	8	weeks	
(g)	 12.0	±	0.4	 13.4	±	0.6	 12.5	±	0.5	 0.1436	
Bone	mineral	content	at	16	
weeks	(g)	 13.9	±	0.7	b	 15.8	±	0.4	a	 14.0	±	0.6	b	 0.0382	
Bone	mineral	density	at	8	weeks	
(g/cm2)	 0.172	±	0.002	 0.179	±	0.003	 0.176	±	0.003	 0.1436	
Bone	mineral	density	at	16	
weeks	(g/cm2)	 0.178	±	0.002	 0.178	±	0.003	 0.181	±	0.003	 0.6994	
Total	lean	mass	at	8	weeks	(g)	 269	±	7	b	 306	±	12	a	 300	±	9	a	 0.0119	
Total	lean	mass	at	16	weeks	(g)	 293	±	4	 301	±	9	 305	±	10	 0.5852	
Total	fat	mass	at	8	weeks	(g)	 90	±	8	 128	±	12	 113	±	13	 0.0633	
Total	fat	mass	at	16	weeks	(g)	 89	±	5	c	 189	±	6	a	 125	±	12	b	 <	0.0001	
Abdominal	circumference	at	8	
weeks	(cm)	 18.9	±	0.5	b	 21.4	±	0.4	a	 20.2	±	0.3	a	 0.0006	
Abdominal	circumference	at	16	
weeks	(cm)	 19.4	±	0.2	c	 22.3	±	0.2	a	 20.3	±	0.2	b	 <	0.0001	
Visceral	adiposity	index	(%)	 5.6	±	0.3	b	 8.6	±	0.3	a	 5.7	±	0.4	b	 <	0.0001	
Tissue	wet	weight	at	16	weeks	(mg/mm	tibial	length)	
Retroperitoneal	fat	 241.4	±	9.8	b	 466.0	±	18.6	a	 253.9	±	21.6	b	 <	0.0001	
Epididymal	fat	 107.7	±	7.7	b	 183.2	±	14.5	a	 109.6	±	14.2	b	 0.0001	
Omental	fat	 141.4	±	8.2	b	 227.5	±	7.7	a	 149.6	±	12.8	b	 <	0.0001	
Total	abdominal	fat	 490.5	±	20.2	b	 876.7	±	23.0	a	 513.1	±	45.4	b		 <	0.0001	
Interscapular	brown	fat	 29.1	±	2.3	b	 37.1	±	2.0	a	 29.5	±	1.7	b	 0.0432	
Left	ventricle	and	septum	 23.0	±	0.9	 23.3	±	1.1	 22.3	±	0.9	 0.7484	
Right	ventricle	 5.0	±	0.3	 5.0	±	0.2	 4.9	±	0.3	 0.8679	
Spleen	 17.7	±	0.8	 18.5	±	0.7	 17.1	±	0.8	 0.4560	
Liver	 242.1	±	6.2	b	 333.2	±	8.2	a	 259.5	±	6.7	b		 <	0.0001	








groups	 (Table	3–4).	Visceral	 adiposity	and	 retroperitoneal	 fat	mass	were	 significantly	























Variable	 H8	 H8C1	 H8C2	 H8C4	 H8C8	 P–value	
Bone	mineral	content	(g)	 12.9	±	0.4	 13.6	±	0.6		 13.5	±	0.6	 14.2	±	0.7	 14.0	±	0.6	 0.6456	
Bone	mineral	density	(g/cm2)	 0.177	±	0.004	 0.183	±	0.003	 0.185	±	0.003	 0.182	±	0.004	 0.181	±	0.003	 0.6630	
Total	lean	mass	(g)	 310	±	9	 307	±	7	 310	±	9	 300	±	11	 305	±	10	 0.9350	
Total	fat	mass	(g)	 127	±	13	 123	±	17	 115	±	13	 135	±	17	 125	±	12	 0.9260	
Abdominal	circumference	(cm)	 20.2	±	0.2	 20.1	±	0.4	 20.3	±	0.3	 20.5	±	0.3	 20.3	±	0.2	 0.9018	
Visceral	adiposity	(%)	 8.0	±	0.4	a	 6.9	±	0.5	ab	 6.6	±	0.3	ab	 6.8	±	0.4	ab	 5.7	±	0.4	b	 0.0054	
Tissue	wet	weight	(mg/mm	tibial	length)	
Retroperitoneal	fat	 394.6	±	32.8	a	 341.8	±	31.2	ab	 334.9	±	25.2	ab	 330.2	±	27.5	ab	 253.9	±	21.6	b	 0.0219	
Epididymal	fat	 142.2	±	9.9	 156.4	±	14.9	 142.1	±	12.6	 124.5	±	13.4	 109.6	±	14.2	 0.1215	
Omental	fat	 251.2	±	11.1	a	 204.4	±	16.7	b	 176.2	±	12.8	bc	 184.3	±	10.7	bc	 149.6	±	12.8	c	 <	0.0001	
Total	abdominal	fat	 787.9	±	47.1	a	 694.7	±	62.2	a	 653.2	±	34.1	ab	 639.0	±	45.9	ab	 513.1	±	45.4	b	 0.0055	
Interscapular	brown	fat	 32.8	±	2.1	 27.0	±	2.1	 27.1	±	2.1	 27.8	±	1.9	 29.5	±	2.3	 0.2269	
Left	ventricle	and	septum	 22.6	±	1.3	 24.8	±	1.0	 25.5	±	0.7	 24.8	±	1.3	 22.3	±	0.9	 0.1158	
Right	ventricle	 4.9	±	0.4	 5.7	±	0.2	 5.0	±	0.4	 5.0	±	0.5	 4.9	±	0.3	 0.1749	
Spleen	 18.8	±	0.9	 16.8	±	0.8	 16.8	±	0.7	 16.8	±	1.2	 17.1	±	0.8	 0.4490	
Liver	 314	±	7.8	a	 261	±	10.3	b	 276	±	11.8	b	 244	±	11.5	b	 260	±	6.7	b	 0.0001	









significantly	 (Table	 3–6).	 A	 significant	 decrease	 in	 alanine	 transaminase	 (ALT)	 was	
observed	 for	 the	 H8C4	 rats	 in	 comparison	 to	 the	 H8C1	 rats	 (P	 <	 0.05)	 and	 although	
aspartate	transaminase	(AST)	was	noticeably	lower	for	the	H8C8	rats	compared	to	the	
H8,	H8C1,	H8C2	 and	H8C4	 rats,	 these	 changes	were	not	 statistically	 significant.	 Total	
cholesterol	was	significantly	greater	for	the	H8	rats	in	comparison	to	the	H8C1	and	H8C8	








Variable	 C	 H	 H8C8	 P–value	
Glucose	tolerance	
Area	under	curve	(mmol/min) 625	±	31	b	 734	±	33	a	 595	±	24	b	 0.0062	
Plasma	liver	enzymes	
Alanine	transaminase	(U/L)	 31	±	4	 53	±	10	 35	±	10	 0.1780	
Aspartate	transaminase	(U/L)	 84	±	3	b	 131	±	19	a	 85	±	6	b	 0.0438	
Plasma	lipid	profile	
Total	cholesterol	(mmol/L)	 1.60	±	0.14	 1.79	±	0.09	 1.33	±	0.09	 0.0688	
Triglycerides	(mmol/L)	 0.81	±	0.05	b	 1.78	±	0.27	a	 0.60	±	0.19	b	 0.0058	
Non‐esterified	fatty	acids	









Variable	 H8	 H8C1	 H8C2	 H8C4	 H8C8	 P–value	
Glucose	tolerance	
Area	under	curve	(mmol/min)	 543	±	16	ab	 544	±	13	ab	 579	±	12	a	 498	±	9	b	 595	±	24	a	 0.0021	
Plasma	liver	enzymes	
Alanine	transaminase	(U/L)	 40	±	2	ab	 45	±	3	a	 37	±	2	ab	 31	±	3	b	 35	±	1	ab	 0.0145	
Aspartate	transaminase	(U/L)	 103	±	4	 109	±	6	 105	±	5	 101	±	5	 85	±	6	 0.2732	
Plasma	lipid	profile	
Total	cholesterol	(mmol/L)	 1.72	±	0.06	a	 1.30	±	0.07	b	 1.63	±	0.05	ac	 1.52	±	0.05	ac	 1.33	±	0.09	bc	 <	0.0001	
Triglycerides	(mmol/L)	 1.47	±	0.24	a	 0.72	±	0.10	b	 0.74	±	0.09	b	 0.66	±	0.09	b	 0.60	±	0.19	b	 0.0008	
Non‐esterified	fatty	acids	





































high‐fat	 diet	 for	 8	 weeks	 then	 switched	 to	 a	 corn	 starch	 diet	 for	 4	 weeks;	H8C8,	 rats	 fed	 a	 high‐
carbohydrate,	high‐fat	diet	for	8	weeks	then	switched	to	a	corn	starch	diet	for	8	weeks.	
A	












































































































































to	 the	H	 rats	 (approximately	135–140	mmHg)	at	8	weeks	and	significantly	decreased	












































































































































hearts	 contained	 large	 clusters	 of	 inflammatory	 cells	 (Figure	 3–5).	 The	 diet	 switch	
noticeably	reduced	inflammatory	cell	 infiltration	and	the	heart	tissue	of	the	H8C8	rats	
appeared	similar	 to	 the	C	rats	at	 the	end	of	 the	16–week	protocol.	These	effects	were	


























although	 there	were	 small	 fat	 vacuoles	 and	 clusters	 of	 inflammatory	 cells.	 There	was	
widespread	lipid	deposition	within	the	livers	of	the	H8	and	H8C1	rats,	which	was	visibly	
reduced	within	the	H8C2	rat	livers	and	continued	to	improve	in	the	H8C4	and	H8C8	rats	



































This	 study	 investigated	 the	 attenuation	 of	 diet–induced	 metabolic	 syndrome	 in	 rats	
switched	from	a	diet	rich	in	simple	carbohydrates	and	saturated	fats	to	a	 low–fat,	 less	
energy–dense	diet.	Consumption	of	the	HCHF	diet	for	8	weeks	induced	the	characteristic	
traits	 of	metabolic	 syndrome,	 including	 increased	 abdominal	 adiposity,	 hypertension,	















least	8	weeks,	which	 is	 consistent	with	previous	 studies	 that	have	utilised	 this	model	
(Bhaswant	et	al.	2015;	Panchal	et	al.	2011;	Wanyonyi	et	al.	2017).	The	obesogenic	nature	
of	the	HCHF	diet	is	not	only	due	to	the	high	content	of	trans	and	saturated	fats	in	the	beef	
tallow,	 as	 fructose	has	also	been	 strongly	 implicated	 in	 the	development	of	metabolic	
38	
syndrome	 (Bahadoran	 et	 al.	 2017;	 Ishimoto	 et	 al.	 2013;	 Lozano	 et	 al.	 2016).	 Despite	
having	 a	 similar	 molecular	 structure	 to	 glucose	 and	 an	 equivalent	 caloric	 value,	 the	



































obesogenic	 diet	 to	 a	 low–fat	 diet	 and	 this	 has	 been	 attributed	 to	 the	 incomplete	































increased	 sympathetic	 nervous	 system	 activity	 mediated	 by	 the	 dorsomedial	









2018).	 The	 diet	 switch	 may	 have	 reduced	 diastolic	 stiffness	 due	 to	 a	 change	 in	
myocardial	energetics	(Rider	et	al.	2013).		










was	 that	switching	 from	the	HCHF	diet	 to	 the	CS	diet	 led	 to	a	 reduction	 in	abdominal	
adiposity,	which	subsequently	decreased	fat	deposition	within	the	liver,	reduced	heart	
inflammation,	 improved	diastolic	 function	and	 lowered	systolic	blood	pressure.	These	
health	benefits	occurred	despite	minimal	weight	loss	after	the	diet	switch,	which	suggests	







an	 enzyme–linked	 immunosorbent	 assay	 (ELISA)	 could	 be	 performed	 on	 the	 plasma	
samples	collected	 in	this	study	to	analyse	satiety	hormone	concentrations.	The	rate	at	














Reverse	 transcription	 polymerase	 chain	 reaction	 (RT‐PCR)	 could	 provide	 additional	
insight	into	the	molecular	changes	that	occur	as	a	result	of	switching	to	the	corn	starch	
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